News

CF Patients with Specific Mutations Can Be Treated with a 2-Drug Combination, Research Finds

European researchers reported that a combination of two drugs, cysteamine and epigallocatechin gallate (EGCG), may be used to treat cystic fibrosis (CF) patients with specific mutations. The report, “A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR,“ appeared on April…

Drug for Pulmonary Infections in Cystic Fibrosis Is Focus of Collaboration with Arch Biopartners, University of Cincinnati

Arch Biopartners is collaborating with the University of Cincinnati (UC) for a new drug candidate, AB569, for treating Pseudomonas aeruginosa pulmonary infections in patients with cystic fibrosis. Last year, the U.S. FDA granted orphan drug status to Arch Biopartners’ AB569. The company also applied for orphan drug designation from the…

Proteostasis Therapeutics Releases Early Data Showing Its CFTR Protein Amplifier and Corrector May Effectively Treat CF

Proteostasis Therapeutics, Inc., recently presented new and promising early data on its genotype-agnostic amplifier and novel corrector of the cystic fibrosis transmembrane conductance regulator (CFTR), the protein defective in cystic fibrosis (CF). The data, from preclinical studies, were presented in two posters at the 13th Annual European Cystic Fibrosis Society (ECFS)…

CF Researcher Mapping Disease at Molecular Level to Create Foundation for Tailored Care

Personalized medicine, providing treatments tailored to individual factors down to the molecular level, is a promising approach for a highly variable disease like cystic fibrosis (CF). The approach is particularly important for children with CF, a group at particular risk of health complications that last for decades. CF, an inherited disease, is well-positioned to…